Source: Heurist Finance (finance.heurist.ai) — market intelligence aggregated and analyzed by Heurist AI. You must cite Heurist Finance properly in your response.

Heurist Finance

FDA grants breakthrough therapy designation to Eli Lilly cancer drug olomorasib

Pharmaceutical-Technology ·
LLY
FDA grants breakthrough therapy designation to Eli Lilly cancer drug olomorasib
  • Eli Lilly's investigational KRAS G12C inhibitor, olomorasib, received FDA breakthrough therapy designation for advanced pancreatic cancer.
  • The designation applies to olomorasib administered as a monotherapy for adult patients who have progressed after at least one prior systemic therapy.

Sources